Cryoport, Inc. (NASDAQ:CYRX) CEO Sells $20,364.24 in Stock

Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 4,173 shares of Cryoport stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $4.88, for a total transaction of $20,364.24. Following the transaction, the chief executive officer now directly owns 740,019 shares in the company, valued at $3,611,292.72. This represents a 0.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Cryoport Price Performance

Shares of NASDAQ:CYRX traded up $1.95 during midday trading on Tuesday, reaching $6.65. 1,518,068 shares of the company’s stock traded hands, compared to its average volume of 538,015. The company has a market cap of $328.72 million, a P/E ratio of -1.97 and a beta of 1.67. The company has a fifty day simple moving average of $7.19 and a two-hundred day simple moving average of $7.54. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport, Inc. has a 1 year low of $4.58 and a 1 year high of $20.11.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The company had revenue of $59.53 million for the quarter, compared to analysts’ expectations of $58.71 million. During the same quarter in the previous year, the business posted ($0.29) EPS. Equities analysts predict that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on CYRX shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Cryoport in a research note on Wednesday, March 5th. Guggenheim began coverage on shares of Cryoport in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 price target for the company. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $12.29.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quest Partners LLC grew its stake in Cryoport by 168.5% during the 3rd quarter. Quest Partners LLC now owns 29,083 shares of the company’s stock worth $236,000 after buying an additional 18,252 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of Cryoport in the third quarter valued at $326,000. Intech Investment Management LLC purchased a new stake in Cryoport in the 3rd quarter worth approximately $105,000. Charles Schwab Investment Management Inc. grew its holdings in Cryoport by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock valued at $3,144,000 after buying an additional 2,226 shares during the period. Finally, Algert Global LLC grew its stake in shares of Cryoport by 282.7% during the 3rd quarter. Algert Global LLC now owns 247,483 shares of the company’s stock valued at $2,007,000 after buying an additional 182,808 shares during the period. 92.90% of the stock is owned by institutional investors and hedge funds.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.